Valeria Piazzolla

Medicine & Life Sciences

1. Genotype 100%
2. Hepacivirus 98%
3. Ribavirin 98%
4. Sofosbuvir 70%
5. velpatasvir 37%
6. Fibrosis 35%
7. Interferons 30%
8. Infections 29%
9. Hepatitis C Antibodies 25%
10. Interleukins 25%
11. Therapeutics 24%
12. Virus Diseases 23%
13. Antiviral Agents 23%
14. Sustained Virologic Response 21%
15. Chronic Hepatitis C 20%
16. RNA 19%
17. Genome-Wide Association Study 18%
18. vesatolimod 16%
19. Names 16%
20. inosine triphosphatase 15%
21. Italy 15%
22. N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide 15%
23. Coronavirus 14%
24. Alleles 13%
25. Liver Diseases 13%
26. sofosbuvir drug combination ledipasvir 13%
27. Duration of Therapy 13%
28. BMS-790052 13%
29. HLA-DQB1 antigen 12%
30. Hepatitis B virus 12%
31. Chronic Hepatitis B 12%
32. Inosine Triphosphatase Deficiency 11%
33. Liver 11%
34. Interferon alpha-2 11%
35. Tenofovir 11%
36. Hepatitis Viruses 10%
37. Life Change Events 10%
38. T-Lymphocytes 10%
39. Thalassemia 10%
40. Single Nucleotide Polymorphism 10%
41. Portal Hypertension 9%
42. Multicenter Studies 9%
43. Non-alcoholic Fatty Liver Disease 9%
44. Elasticity Imaging Techniques 9%
45. Chronic Hepatitis 9%
46. Genes 8%
47. Hepatitis B 8%
48. Anemia 8%
49. Vaccines 8%
50. Natural Killer Cells 8%